The Lynx Group

New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Videos

Featuring:

Sanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Hospital and Temple University
Philadelphia, PA

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: